Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — UBS Global Healthcare Conference 2013
20 slides from Angiodynamics's conference presentation, May 21, 2013
Slide 1: AngioDynamics UBS Global Healthcare Conference, May 2013
Joseph DeVivo, President and CEO Mark Frost, EVP and CFO May 2013 AngioDynamics, the AngioDynamics logo and other trademarks displayed in this presentation are trademarks owned and used by AngioDynamics, Inc. © Copyright 2012 AngioDynamics, Inc. All rights reserved.
Slide 2: Forward-Looking Statements
* FORWARD-LOOKING STATEMENTS Notice Regarding Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations
Slide 3: AngioDynamics at a Glance
* ANGIODYNAMICS AT A GLANCE Corporate History Founded 1988 | IPO May 2004 | ANGO (NASDAQ) Acquired Vortex Medical (2012) |Navilyst (2012) | Oncobionic (2008) | RITA Medical (2007) Worldwide Presence Albany NY – HQ | 1,400 Employees | 7 Operating Locations
Slide 4: The AngioDynamics Mission: A New Day for AngioDynamics
* The AngioDynamics Mission A NEW DAY FOR ANGIODYNAMICS Vascular Access VA Peripheral Vascular PV Oncology/ Surgery O/S BioFlo as a platform technology Advanced techniques & procedures New technologies Automated fluid management Comprehensive venous strategy Thrombolysis/thrombectomy/PE Next generat
Slide 5: Peripheral Vascular Business
* PERIPHERAL VASCULAR BUSINESS Reinvigorate NAMIC Expand Ablation Grow Core PV Peripheral Vascular Drive AngioVac Adoption Channel Synergy Fluid Management in IR/Vascular Venous Ablation in Cardiology Core Products in Cardiology NeverTouch Direct Launch Strategic Objectives Key Growth Drivers (1) Pr
Slide 6: Vortex Medical
* VORTEX MEDICAL A highly differentiated endovascular device Facilitates en bloc removal of undesirable intravascular material Large, established unmet market opportunity FDA cleared, with encouraging early market traction; 400 cases performed to date Synergistic call points – cardiac and vascular
Slide 7: AngioVac Procedure
AngioVac Procedure Introducing a AngioVac Cannula and Circuit Designed to facilitate en-bloc removal of undesirable intravascular material during the performance of extracorporeal circulation. ; ® angiodynamics
Slide 8: VenaCure EVLT
* VENACURE EVLT PV The Power of Water… 30M People in U.S. w/ varicose veins Large Underpenetrated Market Opportunity <2% Receive treatment $240 million Global market, with 10-15% CAGR 100,000+ VenaCure EVLT procedures in FY2013 ANGO has 25% share of Venous Ablation market and 50% share of the Lase
Slide 9: Vascular Access Business
* VASCULAR ACCESS BUSINESS Penetrate & Convert BIOFLO BIOFLO BIOFLO VA Vascular Access BioFlo PICCs Received FDA 510(k) clearance BioFlo Ports & BioFlo Dialysis Catheters 510(k)s planned for FY13 Tip Location Distribution agreement Strategic Acquisitions Strategic Objectives Key Growth Drivers (1) P
Slide 10: BioFlo Technology
* BIOFLO TECHNOLOGY Estimated Cost Per Incident4 $11,957 PICC-Related UEDVT Incidence Rates2,3 VA 2.7M PICCs placed by nurses & Physicians in 20121 The Big Picture 2Evans SR, Sharp JH, Lorraine LH, et al. CHEST 2010; 138; 803-810 1US MARKETS FOR VASCULAR ACCESS DEVICES 2012 - Millennium Research Gro
Slide 11: BioFlo Technology: A Revolutionary PICC Technology
* Coatings (on the surface) Impregnated (in the pores) Current Next Generation PICC Technologies NO HEPARIN NO ANTIBIOTICS NOT A COATING NOT ELUTING Minimizes complications associated w/ heparin Reduces risks associated w/ bacterial resistance Present throughout entire catheter Present for life of d
Slide 12: BioFlo Technology (cont'd)
* BIOFLO TECHNOLOGY (cont’d) VA 2Presented at INS May 21, 2013. 1Presented at Ohio Association for Healthcare Quality conference on May 17, 2013. Prospective Customer Evaluation of BioFlo Hospital BioFlo PICC Placements (6 months) DVTs DVT RATE Hillcrest1 276 0 0 Cleveland Clinic2 373 1 0.2%
Slide 13: Oncology / Surgery Business
* ONCOLOGY / SURGERY BUSINESS Drive NanoKnife Adoption Deliver the Most Comprehensive Ablation Solution NanoKnife Data International Microwave Embarc Microcatheter & Charter Guidewire launches Strategic Transactions Strategic Objectives Key Growth Drivers Global Net Sales Continue to Fill Channel (1
Slide 14: Microsulis
* Microsulis We believe Microsulis is the leading microwave tumor ablation technology on the market today “Everything we wanted in a microwave device…” -Current AngioDynamics RFA Customer 2.45Ghz system for faster tissue penetration Single applicator 5 cm ablation Fast ablation times Predictable vol
Slide 15: Expanding Our Leadership in Tumor Ablation
* AngioDynamics offers a full complement of tumor ablation products that provide clinicians maximum choice in treating patients THERMAL NON-THERMAL “The US Nonvascular Interventional Radiology market with the fastest growth and greatest potential is the ablation device market” – MRG Nov. 2012 EXPAND
Slide 16: Navilyst Integration
* Expecting $7-10M in FY13 cost savings & at least $15 million in FY14 Organizational changes completed Management team now in place – best talent from both organizations New CFO New Chief Tech/Ops Officer Creation of three global businesses to achieve greater focus on customers and markets NAVILYST
Slide 17: Fiscal 2013 Q3 Results
* FISCAL 2013 Q3 RESULTS $ in millions, except per share amounts Pro Forma(a) 3 months ended Feb 28, 2013(b) Reported YOY Growth WW Sales $81.6 58% % growth (2%) 58% Vascular Sales $69.0 82% % growth (4%) 82% Onc/Surg Sales $10.4 (23%) % growth 10% (23%) U.S. Sales $65.9 51% % growth (5%) 51% Int’l
Slide 18: Fiscal 2013 Guidance
* FISCAL 2013 GUIDANCE $ in millions, except per share amounts Adjusted Non-GAAP Q4 Adjusted Non-GAAP Full Year Sales (a) $85 — $89 $337 — $341 EBITDA (b)(c) $10 — $12 $50 — $52 EPS (d) $0.04 — $0.07 $0.32 — $0.35 Fiscal Year 2012 pro forma combined sales excluding LC Beads were $344.3 million. Adju
Slide 19: Investment Summary
* INVESTMENT SUMMARY Three global business focused on innovation with multiple growth drivers Optimized R&D organization to enhance new product pipeline Adding products with high growth potential such as BioFlo and AngioVac Significantly improving quality management system Rapid growth from internat
Slide 20: AngioDynamics, the AngioDynamics logo and other trademSarks displayed in this presentation are trademarks owned
AngioDynamics, the AngioDynamics logo and other trademSarks displayed in this presentation are trademarks owned and used by AngioDynamics, Inc. © Copyright 2012 AngioDynamics, Inc. All rights reserved.
AngioDynamics — UBS Global Healthcare Conference 2013 on 6ix